Vanda Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed on February 19, 2026, covering events that occurred on February 18, 2026. The filing details the Compensation Committee's decisions regarding executive compensation, including the awarding of 2025 annual bonuses, the approval of 2026 base salaries and bonus targets, and the granting of new equity awards to named executive officers.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- 2025 Annual Bonuses Awarded: Total bonuses awarded to five named executive officers ranged from $272,129 to $834,326.
- 2026 Base Salaries Approved: Annual base salaries for 2026 range from $576,735 to $994,625.
- 2026 Bonus Targets: Target bonus percentages for 2026 range from 45% to 80% of base salary.
- Equity Grants: Restricted Stock Units (RSUs) and Performance Restricted Stock Units (PSUs) were granted, with the CEO receiving 525,000 RSUs and 175,000 target PSUs.
Material Changes
The filing reports specific changes to executive compensation structures effective for the 2026 fiscal year:
- Salary Adjustments: Base salaries for 2026 have been set, with the CEO's salary established at $994,625.
- Equity Structure: New RSU awards vest in four equal annual installments starting March 1, 2027. New PSU awards are tied to a three-year performance period (Dec 31, 2025, to Dec 31, 2028) based on Relative Total Stockholder Return (TSR) against the Nasdaq Biotechnology Index.
- Performance Metrics: PSU payouts range from 0% to 150% of the target award based on TSR percentile rankings (25th to 75th percentile).
Guidance, Outlook, and Risks
The filing contains no financial guidance, revenue outlook, or general risk factors. The primary contingency noted is that PSU awards are subject to the executive's continued employment through the certification of performance following the end of the Performance Period on December 31, 2028. No dividends are paid or accrued on the PSUs.
Key Facts for Investor Verification
- Verify the total cash outflow for 2025 bonuses ($2,032,399 total for the five named officers) against the company's current cash position.
- Confirm the impact of the new 2026 base salaries and bonus targets on future operating expenses.
- Review the specific vesting schedules for the 525,000 RSUs granted to the CEO and the performance hurdles for the 175,000 PSUs.
- Check the company's stock price performance relative to the Nasdaq Biotechnology Index to assess the likelihood of PSU payout thresholds being met.